READ-ONLY DIGITIZATION RESULT
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.
Blood · 2025-Jun-05 · PMID 40009494
Panel D提取完成待 EXE 对齐验证
DOR
Figure 1. Kaplan-Meier estimates of efficacy end points in the overall intent-to-treat population. Investigator-assessed PFS (A), OS (B), EFS (C), and DOR (D). Log-rank test and Cox proportional hazards regression model were used to compare overall PFS and OS across treatment arms. EFS, event-free survival.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-23T17:46:24+00:00 |